{
    "root": "90f1b2dd-1f14-e002-60ff-7a39a009b6e3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ambrisentan",
    "value": "20250429",
    "ingredients": [
        {
            "name": "AMBRISENTAN",
            "code": "HW6NV07QEC"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "ALUMINUM OXIDE",
            "code": "LMI26O6933"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients:\n                  \n                     To improve exercise ability and delay clinical worsening. \n                  \n                  Studies establishing effectiveness included predominantly patients with WHO Functional Class IIâ€“III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).",
    "contraindications": "Initiate treatment at 5 mg once daily ( 2.1 ). Titrate at 4-week intervals as needed and tolerated ( 2.1 ). Do not split, crush, or chew tablets ( 2.1 ).",
    "warningsAndPrecautions": "Ambrisentan film-coated tablets are supplied as follows:\n                  Each 5 mg tablet is pale pink, biconvex, beveled edged, arc square film-coated tablet. Engraved \"APO\" on one side, \"A5\" on the other side.\n                  Bottles of 30 tablets NDC 60505-4552-3 Blisters of 10 (1 x 10 blister pack) NDC 60505-4552-0 Blisters of 30 (3 x 10 blister pack) NDC 60505-4552-1\n                  Each 10 mg tablet is deep pink, biconvex, oval film-coated tablet. Engraved \"APO\" on one side, \"A10\" on the other side.\n                  Bottles of 30 tablets NDC 60505-4553-3 Blisters of 10 (1 x 10 blister pack) NDC 60505-4553-0 Blisters of 30 (3 x 10 blister pack) NDC 60505-4553-1",
    "adverseReactions": "Pregnancy ( 4.1 ) Idiopathic Pulmonary Fibrosis ( 4.2 )"
}